Served as partial requirement for the Master degree in Clinical Pharmacy of the Hebrew University.
Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study
Article first published online: 11 JUL 2008
© 2008 The Authors. Journal compilation © 2008 Blackwell Publishing Ltd
British Journal of Clinical Pharmacology
Volume 66, Issue 5, pages 695–705, November 2008
How to Cite
Diav-Citrin, O., Shechtman, S., Weinbaum, D., Wajnberg, R., Avgil, M., Di Gianantonio, E., Clementi, M., Weber-Schoendorfer, C., Schaefer, C. and Ornoy, A. (2008), Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. British Journal of Clinical Pharmacology, 66: 695–705. doi: 10.1111/j.1365-2125.2008.03261.x
- Issue published online: 28 OCT 2008
- Article first published online: 11 JUL 2008
- Received 29 April 2008Accepted1 July 2008
- cardiovascular anomalies;
- congenital anomalies;
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• In recent years there has been concern regarding the possibility that selective serotonin reuptake inhibitors (SSRIs) cause an increased rate of congenital cardiovascular anomalies.
• As of today, there is still debate in the literature as to the possible effects of paroxetine and fluoxetine on the embryonic cardiovascular system.
WHAT THIS STUDY ADDS
• Based on prospective data from three Teratogen Information Services, we have demonstrated an increased rate of congenital cardiovascular anomalies among the offspring of fluoxetine- and paroxetine-treated mothers.
Recent studies have suggested a possible association between maternal use of selective serotonin reuptake inhibitors (SSRIs) in early pregnancy and cardiovascular anomalies. The aim of the present study was to evaluate the teratogenic risk of paroxetine and fluoxetine.
This multicentre, prospective, controlled study evaluated the rate of major congenital anomalies after first-trimester gestational exposure to paroxetine, fluoxetine or nonteratogens.
We followed up 410 paroxetine, 314 fluoxetine first-trimester exposed pregnancies and 1467 controls. After exclusion of genetic and cytogenetic anomalies, there was a higher rate of major anomalies in the SSRI groups compared with the controls [paroxetine 18/348 (5.2%), fluoxetine 12/253 (4.7%) and controls 34/1359 (2.5%)]. The main risk applied to cardiovascular anomalies [paroxetine 7/348 (2.0%), crude odds ratio (OR) 3.47, 95% confidence interval (CI) 1.13, 10.58; fluoxetine 7/253 (2.8%), crude OR, 4.81 95% CI 1.56, 14.71; and controls 8/1359 (0.6%)]. On logistic regression analysis only cigarette smoking of ≥10 cigarettes day−1 and fluoxetine exposure were significant variables for cardiovascular anomalies. The adjusted ORs for paroxetine and fluoxetine were 2.66 (95% CI 0.80, 8.90) and 4.47 (95% CI 1.31, 15.27), respectively.
This study suggests a possible association between cardiovascular anomalies and first-trimester exposure to fluoxetine.